Overview

A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia

Status:
Completed

Trial end date:
2021-01-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether add-on TAK-831 is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).

Phase:

Phase 2

Details

Lead Sponsor:

Neurocrine Biosciences

Collaborator:

Takeda